{
  "meta": {
    "title": "00246_Mid_Day_Module_Medicine-2",
    "url": "https://brainandscalpel.vercel.app/00246-mid-day-module-medicine-2-57ac92cd.html",
    "scrapedAt": "2025-11-29T18:14:41.555Z"
  },
  "questions": [
    {
      "id": 53940,
      "choices": [
        {
          "id": 215229,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 years </span></span></span></p>"
        },
        {
          "id": 215230,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8 years </span></span></span></p>"
        },
        {
          "id": 215231,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 years </span></span></span></p>"
        },
        {
          "id": 215232,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">15 years</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Screening for Parathyroid disorder in MEN 1 should begin at the age of?</span></span></p>",
      "unique_key": "Q8666884",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368749,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 8 years</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary hyperparathyroidism (PHPT) is the most common and often the earliest manifestation of MEN1. While it usually manifests in adulthood, cases have been reported in children as young as 4 years old. Therefore, current guidelines recommend starting biochemical screening for PHPT with annual serum calcium and PTH measurements at 8 years of age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-175419.png\" style=\"height:454px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 5 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for anterior pituitary tumours &amp; insulinomas begin in MEN1. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 20 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for gastrinomas begin in MEN 1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 15 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is when screening for carcinoids (thymic/bronchial) begin in MEN 1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Screening for primary hyperparathyroidism in MEN1 should begin at 8 years of age.</span></span></span></p>",
      "correct_choice_id": 215230,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54029,
      "choices": [
        {
          "id": 215585,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck exploration under general anesthesia. </span></span></span></p>"
        },
        {
          "id": 215586,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Check Mg levels. </span></span></span></p>"
        },
        {
          "id": 215587,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neck Ultrasound to look for parathyroids. </span></span></span></p>"
        },
        {
          "id": 215588,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Add Cinacalcet.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 64-year-old female with PHPT underwent parathyroidectomy. On POD 4, she experiences persistent hypocalcemia with low PTH levels, requiring continuous IV calcium infusion to maintain S.Ca. Which of the following is the most appropriate next step?</span></span></span></p>",
      "unique_key": "Q4521906",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368745,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Check Mg levels.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Persistent hypocalcemia with low PTH levels after parathyroidectomy suggests hypoparathyroidism. However, hypomagnesemia is an important cause of hypoparathyroidism post-op and cause hypocalcemia by impairing PTH secretion and action. Therefore, checking magnesium levels is the most appropriate next step, as correcting hypomagnesemia may resolve the hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Neck exploration under general anesthesia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This is invasive and usually done if there is persistent hyperparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Neck Ultrasound to look for parathyroids:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Will not be providing any useful information in a post-op patient with hypoparathyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Add Cinacalcet:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Cinacalcet is a calcimimetic that lowers PTH,&nbsp;which is already low in this patient.&nbsp;It would be inappropriate and potentially worsen hypocalcemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient who has persistent hypocalcemia and low PTH levels post-parathyroidectomy, the most appropriate next step is to <strong>check magnesium levels</strong>.</span></span></span></p>",
      "correct_choice_id": 215586,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 39117,
      "choices": [
        {
          "id": 156203,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone suppression </span></span></span></p>"
        },
        {
          "id": 156204,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT of adrenals </span></span></span></p>"
        },
        {
          "id": 156205,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma renin and aldosterone </span></span></span></p>"
        },
        {
          "id": 156206,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urine metanephrines</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 36-year-old man presents to the clinic reporting ankle swelling. On examination, his blood pressure is elevated at 162/86, and he has bilateral ankle edema. Laboratory studies show a potassium of 2.9 and normal creatinine. Which of the following studies is recommended next?</span></span></p>",
      "unique_key": "Q9578795",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368759,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Plasma renin and aldosterone</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient presents with hypertension, hypokalemia, and edema, which are classic signs of hyperaldosteronism. Plasma renin and aldosterone levels are the initial screening tests for primary aldosteronism. This test helps to determine if the aldosterone excess is due to an adrenal problem (primary aldosteronism) or if it&#39;s a result of another issue stimulating the adrenal glands to produce aldosterone (secondary aldosteronism).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dexamethasone suppression:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose Cushing&#39;s syndrome (excess cortisol production). While Cushing&#39;s syndrome can cause hypertension, it is not typically associated with hypokalemia and edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. CT of adrenals:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This imaging study can be useful to identify adrenal tumors, but it should be performed after biochemical confirmation of hyperaldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Urine metanephrines:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose pheochromocytoma, a tumor that produces catecholamines. While pheochromocytoma can cause hypertension, it is not typically associated with hypokalemia and edema.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (hypertension, hypokalemia, and edema) suggests hyperaldosteronism. The initial test should be measuring plasma renin and aldosterone levels to confirm the diagnosis and determine if the cause is primary (adrenal) or secondary.</span></span></span></p>",
      "correct_choice_id": 156205,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53965,
      "choices": [
        {
          "id": 215329,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated 17-hydroxyprogesterone (17-OHP) levels </span></span></span></p>"
        },
        {
          "id": 215330,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased serum 11-deoxycorticosterone (11-DOC) levels </span></span></span></p>"
        },
        {
          "id": 215331,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated DHEA-S (dehydroepiandrosterone sulfate) levels </span></span></span></p>"
        },
        {
          "id": 215332,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Decreased plasma renin activity</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A newborn presents with ambiguous genitalia, clitoromegaly and partial fusion of the labio-scrotal folds. The newborn also shows hyperpigmentation and hypertension. Karyotype shows 46,XX. Which of the following laboratory findings would be most consistent with the diagnosis?</span></span></p>",
      "unique_key": "Q7774887",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368765,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Increased serum 11-deoxycorticosterone (11-DOC) levels</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of ambiguous genitalia, hyperpigmentation, and hypertension in a 46,XX infant is highly suggestive of congenital adrenal hyperplasia (CAH). The presence of hypertension differentiates 11&beta;-hydroxylase deficiency from the more common 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In 11&beta;-hydroxylase deficiency: <strong>11-deoxycorticosterone (11-DOC) levels are increased </strong>due to the enzymatic block in the conversion of 11-DOC to aldosterone. Increased 11-DOC results in hypertension with reflex suppression of RAAS. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Elevated 17-OHP levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is primarily seen in 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Elevated DHEA-S levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While DHEA-S is elevated in CAH, it is not specific to 11&beta;-hydroxylase deficiency and is also seen in 21-hydroxylase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Decreased plasma renin activity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is correct for 11&beta;-hydroxylase deficiency, but it is not the most specific finding for this type of CAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated serum 11-deoxycorticosterone (11-DOC) levels are indicative of 11&beta;-hydroxylase deficiency in CAH.</span></span></span></p>",
      "correct_choice_id": 215330,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19945,
      "choices": [
        {
          "id": 79741,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 3 months </span></span></span></p>"
        },
        {
          "id": 79742,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 6 months </span></span></span></p>"
        },
        {
          "id": 79743,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 1 year </span></span></span></p>"
        },
        {
          "id": 79744,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In 5 years</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 50-year-old patient with newly diagnosed type 2 diabetes mellitus (T2DM) has a negative urine microalbumin test. When should the next urine microalbumin test be repeated?</span></span></p>",
      "unique_key": "Q6840122",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368784,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) In 1 year</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended for patients with type 2 diabetes to detect early signs of diabetic nephropathy (kidney disease). A negative test result indicates no current evidence of kidney damage, therefore, the next screening should be done in a year.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-094813.png\" style=\"height:477px; width:1000px\" /></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. In 3 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too frequent for routine screening and not necessary with a negative initial test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. In 6 months:</span></strong><span style=\"font-size:12.0pt\">&nbsp;While more frequent screening may be indicated in some cases,&nbsp;annual testing is generally sufficient for initial monitoring.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. In 5 years:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Too infrequent for monitoring diabetic nephropathy,&nbsp;as significant damage could occur undetected in this time frame.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Annual screening for microalbuminuria is recommended in type 2 diabetes to detect early signs of diabetic nephropathy.</span></span></span></p>",
      "correct_choice_id": 79743,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54028,
      "choices": [
        {
          "id": 215581,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Observation </span></span></span></p>"
        },
        {
          "id": 215582,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroidectomy </span></span></span></p>"
        },
        {
          "id": 215583,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cinacalcet </span></span></span></p>"
        },
        {
          "id": 215584,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bisphosphonates</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old male presents with a serum calcium of 11.2 mg/dL (normal 8.5-10.5) and a parathyroid hormone (PTH) level of 110 pg/mL (normal 15-70 pg/mL). He is otherwise asymptomatic, has normal renal function, and his dual-energy X-ray absorptiometry (DXA) scan is within normal limits. What is the most appropriate management?</span></span></p>",
      "unique_key": "Q8082764",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368744,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Parathyroidectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s elevated serum calcium and PTH levels are indicative of primary hyperparathyroidism (PHPT). Although he is currently asymptomatic, guidelines recommend parathyroidectomy for patients under 50 with PHPT, especially when serum calcium levels are above the upper limit of normal. This is because even asymptomatic PHPT can lead to long-term complications such as osteoporosis, nephrolithiasis, and cardiovascular disease.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Indications for parathyroidectomy in asymptomatic PHPT:</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\">&nbsp;</span></span></p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum calcium (above normal) &gt;1 mg/dL.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal Creatinine clearance &lt;60 mL/min or 24-h Urinary calcium &gt; 400 mg/d + increased stone risk by biochemical stone risk analysis or Presence of stones or nephrocalcinosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Skeletal BMD by DXA: T score &lt;&ndash;2.5 or Vertebral fracture.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Age &lt;50.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Observation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;While observation might be considered in elderly patients with mild PHPT,&nbsp;it is not appropriate for a young,&nbsp;asymptomatic patient with elevated S.Ca levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Cinacalcet:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Cinacalcet is a calcimimetic that can lower PTH and calcium levels.&nbsp;However,&nbsp;it is not a first-line treatment for PHPT and is generally reserved for patients who are not surgical candidates or who have persistent PHPT post-surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Bisphosphonates:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Bisphosphonates can help to prevent bone loss but do not address the underlying cause of hyperparathyroidism,&nbsp;which is excessive PTH secretion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate management for a 43-year-old male with primary hyperparathyroidism (PHPT), elevated serum calcium, and PTH levels is <strong>parathyroidectomy</strong>.</span></span></span></p>",
      "correct_choice_id": 215582,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19914,
      "choices": [
        {
          "id": 79617,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hold atenolol for 1 week and repeat testing </span></span></span></p>"
        },
        {
          "id": 79618,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hold sertraline for 1 week and repeat testing </span></span></span></p>"
        },
        {
          "id": 79619,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start &alpha;-blockers and then &beta;-blockers</span></span></span></p>"
        },
        {
          "id": 79620,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT of the abdomen and pelvis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 43-year-old man with episodic, severe hypertension is referred with mild depression and current medications including sertraline, atenolol, amlodipine, and enalapril. Urine 24-hour total metanephrines show a borderline (1.5x) elevation. What is the next most appropriate step? </span></span></p>",
      "unique_key": "Q2584867",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368756,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Hold atenolol for 1 week and repeat testing</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When the diagnosis of pheochromocytoma is entertained, the first step is measurement of catecholamines and/or metanephrines. Testing for total metanephrines has a high sensitivity and, therefore, is frequently used. A value of &ge; 3x ULN is highly suggestive of pheochromocytoma. Borderline elevations, like in this patient, are likely to be false positives. The next most appropriate step is to remove potentially confounding dietary or drug exposures and repeat the test. Likely culprit drugs include <em><u>levodopa, sympathomimetics, diuretics, tricyclic antidepressants, and alpha and beta blockers</u></em> (atenolol in this case). Sertraline is a selective serotonin reuptake inhibitor, not a TCA. Alternatively, a clonidine suppression test may be ordered.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hold sertraline for 1 week and repeat testing:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Sertraline is a selective serotonin reuptake inhibitor, not a TCA. Hence its unlikely to affect the test. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Start &alpha;-blockers and then &beta;-blockers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This may be the initial management of pheochromocytoma, once the diagnosis is established, but NOT appropriate in this case with borderline metanephrine elevations. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. CT of the abdomen and pelvis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This may be done to localize pheochromocytoma, once biochemical diagnosis is established. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Borderline elevated metanephrines can be influenced by certain medications, including beta-blockers like atenolol. The next step is to stop potentially interfering medications and repeat the test to confirm the diagnosis.</span></span></span></p>",
      "correct_choice_id": 79617,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53981,
      "choices": [
        {
          "id": 215393,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Propylthiouracil</span></span></span></p>"
        },
        {
          "id": 215394,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Methimazole</span></span></span></p>"
        },
        {
          "id": 215395,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioactive Iodine Ablation</span></span></span></p>"
        },
        {
          "id": 215396,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroidectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following should be avoided in children with Graves disease?</span></span></p>",
      "unique_key": "Q8553849",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368777,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves&rsquo; disease in children is usually managed initially with methimazole or carbimazole. Surgery or radioiodine may be indicated for severe or relapsing disease. Propylthiouracil is avoided in view of risk of hepatitis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Methimazole:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Preferred treatment in children with Graves disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioactive Iodine Ablation:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Usually reserved for refractory/severe Graves disease in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroidectomy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Usually reserved for refractory/severe Graves disease in children. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propylthiouracil should be avoided in children with Graves&#39; disease due to the risk of hepatitis.</span></span></p>",
      "correct_choice_id": 215393,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53949,
      "choices": [
        {
          "id": 215265,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&#39;s syndrome </span></span></span></p>"
        },
        {
          "id": 215266,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Addison&#39;s disease </span></span></span></p>"
        },
        {
          "id": 215267,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperparathyroidism</span></span></span></p>"
        },
        {
          "id": 215268,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypothyroidism</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common endocrine manifestation of Carney complex?</span></span></p>",
      "unique_key": "Q8291041",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368752,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Cushing&#39;s syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Carney complex (CNC) is a multiple endocrine neoplasia syndrome characterized by various endocrine tumors and other features. The most common endocrine manifestation is Cushing&#39;s syndrome, which is caused by primary pigmented nodular adrenocortical disease (PPNAD) in the majority of cases. PPNAD leads to excess cortisol production, resulting in the typical features of Cushing&#39;s syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Addison&#39;s disease:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is primary adrenal insufficiency, which is not a typical feature of Carney complex.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While parathyroid adenomas can occur in CNC, they are less common than PPNAD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hypothyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thyroid involvement in CNC is typically in the form of thyroid nodules or cancer, not hypothyroidism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Carney Complex &ndash;</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Features:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Spotty skin pigmentation, <em><u>myxomas</u></em>, <em><u>psammomatous melanotic schwannomas</u></em>, endocrine tumors (adrenal, Sertoli cells, somatotropes, thyroid, ovary).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common endocrine manifestation:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Cushing&#39;s syndrome due to primary pigmented nodular adrenal disease (PPNAD).</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atypical Cushing&#39;s presentation: Patients are often thin, have short stature, muscle/skin wasting, and osteoporosis.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Periodic Cushing&#39;s syndrome: Fluctuating cortisol levels over days or weeks.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Can have paradoxical elevation of cortisol after dexamethasone administration. </span></span></span></li>\r\n</ul>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other endocrine manifestations:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Acromegaly, testicular tumors (Sertoli cell, Leydig cell), thyroid tumors, ovarian cysts, breast duct adenomas.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetics:</span></span></span></li>\r\n</ul>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CNC1: Mutations in PRKAR1A gene (tumor suppressor) on chromosome 17q24.2.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CNC2: Gene on chromosome 2p16 (not yet identified).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common endocrine manifestation of Carney complex is Cushing&#39;s syndrome due to primary pigmented nodular adrenocortical disease (PPNAD).</span></span></span></p>",
      "correct_choice_id": 215265,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19930,
      "choices": [
        {
          "id": 79681,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Give hydrocortisone 100mg IV. </span></span></span></p>"
        },
        {
          "id": 79682,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV insulin infusion.</span></span></span></p>"
        },
        {
          "id": 79683,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV NaHCO3.</span></span></span></p>"
        },
        {
          "id": 79684,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start IV Insulin + Dextrose.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 20-year-old woman presents with abdominal pain, fever and vomiting. She takes insulin for type 1 diabetes. On examination, her mucosa is dry and the appearance is shown in the image. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">You order an ABG and the results are as follows -</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">pH &ndash; 7.29, Na &ndash; 129 mEq/L, K &ndash; 5.6 mEq/L, HCO3- 18 mEq/L, Cl &ndash; 101 mEq/L and her RBS is 89 mg/dL. Her ECG shows sinus tachycardia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Her BP is 80/40 mm Hg and her PR is 122/min. You give an IV fluid bolus and her BP slightly improves. What is the most important treatment?</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-173002.png\" style=\"height:226px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q7220340",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368772,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Give hydrocortisone 100mg IV.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation, including abdominal pain, fever, vomiting, malaise, dry mucosa, and hyperpigmentation, alongside the lab findings of hyponatremia, hyperkalemia, metabolic acidosis (low bicarbonate), and hypotension, is strongly suggestive of an adrenal crisis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most crucial step in managing an adrenal crisis is to administer intravenous hydrocortisone (100mg) to replace the deficient cortisol. This is a life-saving intervention, as untreated adrenal crisis can rapidly progress to shock and death.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Start IV insulin infusion:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While the patient has type 1 diabetes, her current blood glucose is within the normal range, and insulin infusion is not the priority in this emergency situation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Start IV NaHCO3:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Correcting acidosis is important, but the primary concern is addressing the underlying adrenal insufficiency with hydrocortisone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Start IV Insulin + Dextrose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is an initial therapy in hyperkalemia, to transiently lower serum potassium levels. But in adrenal crisis, correction of underlying cause is important by administering hydrocortisone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation is strongly suggestive of an adrenal crisis. Administering intravenous hydrocortisone is the most important treatment to replace the deficient cortisol.</span></span></span></p>",
      "correct_choice_id": 79681,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53967,
      "choices": [
        {
          "id": 215337,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.0 mg/dL </span></span></span></p>"
        },
        {
          "id": 215338,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.3 mg/dL </span></span></span></p>"
        },
        {
          "id": 215339,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">8.5 mg/dL </span></span></span></p>"
        },
        {
          "id": 215340,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">9.0 mg/dL</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old woman with chronic kidney disease presents with muscle cramps and tingling in her fingers. Her serum calcium is 7.7 mg/dL (normal: 8.5-10.5 mg/dL) and serum albumin is 3.0 g/dL (normal range: 3.5-5.0 g/dL). What is her corrected calcium level?</span></span></p>",
      "unique_key": "Q3260716",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368767,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) 8.5 mg/dL</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium is calculated using the following formula:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In this case:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium = 7.5 + 0.8 x (4.0 - 3.0) = 7.7 + 0.8 = 8.5 mg/dL</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Therefore, the patient&#39;s corrected calcium level is 8.5 mg/dL, which is within the normal range.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">To calculate the corrected calcium level in patients with low serum albumin, use the formula: </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Corrected calcium (mg/dL) = Measured calcium (mg/dL) + 0.8 x (4.0 - Albumin [g/dL])</span></span></p>",
      "correct_choice_id": 215339,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53963,
      "choices": [
        {
          "id": 215321,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pathologic examination of her gonads </span></span></span></p>"
        },
        {
          "id": 215322,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum thyroid-stimulating hormone level </span></span></span></p>"
        },
        {
          "id": 215323,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum prolactin level </span></span></span></p>"
        },
        {
          "id": 215324,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old female presents with Tanner stage IV breast development but no menses. Ultrasound confirms a blind vaginal vault and no uterus or cervix. What lab test would be most helpful in finding the etiology of her problem?</span></span></p>",
      "unique_key": "Q1642027",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368757,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Karyotype</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (normal breast development but absent uterus and cervix) suggests M&uuml;llerian agenesis (Mayer-Rokitansky-K&uuml;ster-Hauser syndrome). However, the most important differential diagnosis to consider is complete androgen insensitivity syndrome (CAIS), a disorder of sex development caused by a mutation in the androgen receptor gene. Individuals with CAIS are genetically male (46,XY) but have female external genitalia due to insensitivity to androgens.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A karyotype is the most helpful test in this scenario as it will definitively determine the patient&#39;s genetic sex and help differentiate between M&uuml;llerian agenesis (46,XX) and CAIS (46,XY).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pathologic examination of her gonads:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this can be informative, it is not the first-line test and may not be necessary if the karyotype confirms CAIS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Serum thyroid-stimulating hormone level:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thyroid dysfunction is not a likely cause of this presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Serum prolactin level:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperprolactinemia is not associated with the absence of uterus and cervix.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A karyotype is the most helpful test for differentiating between M&uuml;llerian agenesis and complete androgen insensitivity syndrome (CAIS).</span></span></span></p>",
      "correct_choice_id": 215324,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53991,
      "choices": [
        {
          "id": 215433,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Observation and repeat USG in 6 months </span></span></span></p>"
        },
        {
          "id": 215434,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Fine needle aspiration biopsy (FNA) </span></span></span></p>"
        },
        {
          "id": 215435,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioiodine scanning </span></span></span></p>"
        },
        {
          "id": 215436,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid lobectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 35-year-old woman presents with a palpable thyroid nodule and has normal TSH levels. USG reveals a hypoechoic solid nodule with microcalcifications. Which of the following is the most appropriate next step in management?</span></span></span></p>",
      "unique_key": "Q9929429",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368783,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Fine needle aspiration biopsy (FNA)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TFT is usually normal in solitary nodules (and even in thyroid cancer). The presence of a hypoechoic solid nodule with microcalcifications on ultrasound raises suspicion for malignancy. FNA is the gold standard for evaluating thyroid nodules and is necessary to rule out cancer in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High risk features in USG:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Solid, Hypoechoic, Tall than wide, lobulated/irregular, extra-thyroidal extension, peripheral/rim or punctate/micro calcifications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Observation and repeat USG in 6 months:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This approach is suitable for smaller or less suspicious nodules but not for those with high-risk features like microcalcifications. Delayed diagnosis could lead to potential complications if the nodule is malignant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioiodine scanning:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Useful only if hyperthyroid on TFTs. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroid lobectomy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Surgery is usually reserved for confirmed malignancy or large symptomatic nodules. FNA is required for diagnosis before considering surgery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Papillary thyroid cancer generally has a good prognosis, and its presence is not associated with a poor prognosis compared to other types of thyroid cancer.</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-142646_s0moNWZ.jpg\" style=\"height:815px; width:876px\" /></span></span></p>\r\n\r\n<p>&nbsp;</p>",
      "correct_choice_id": 215434,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53964,
      "choices": [
        {
          "id": 215325,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kallman syndrome </span></span></span></p>"
        },
        {
          "id": 215326,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner syndrome </span></span></span></p>"
        },
        {
          "id": 215327,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital adrenal hyperplasia (CAH) d</span></span></span></p>"
        },
        {
          "id": 215328,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old girl presents with primary amenorrhea. On examination, she is tall and lacks secondary sexual characteristics. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q8746460",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368762,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Swyer syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome, also known as 46,XY gonadal dysgenesis, is a disorder of sex development where individuals have a female phenotype despite having a male karyotype (46,XY). This occurs due to mutations or deletions in the SRY gene, which is responsible for testis development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The following features in the patient&#39;s presentation support the diagnosis of Swyer syndrome:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary amenorrhea:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is due to the absence of functional ovaries.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lack of secondary sexual characteristics:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is caused by a lack of estrogen production from non-functional gonads.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tall stature:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to delayed closure of epiphysis due to lack of sex hormones. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Kallman syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterized by delayed or absent puberty and anosmia (loss of smell). Individuals with Kallman syndrome typically have a normal female karyotype (46,XX).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Turner syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Characterized by short stature, webbed neck, and other features, with a karyotype of 45,X.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Congenital adrenal hyperplasia (CAH):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Typically presents with virilization (development of male sexual characteristics) in females due to excess androgen production. This is the opposite of what is seen in Swyer syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome (46,XY gonadal dysgenesis) is characterized by a female phenotype with a male karyotype and lack of secondary sexual characteristics.</span></span></span></p>",
      "correct_choice_id": 215328,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54023,
      "choices": [
        {
          "id": 215561,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH (Parathyroid Hormone) </span></span></span></p>"
        },
        {
          "id": 215562,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcium</span></span></span></p>"
        },
        {
          "id": 215563,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FGF-23 (Fibroblast Growth Factor 23) </span></span></span></p>"
        },
        {
          "id": 215564,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,25 (OH)2D (Calcitriol)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1&alpha;-hydroxylase in the kidneys?</span></span></p>",
      "unique_key": "Q4067794",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368741,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) PTH (Parathyroid Hormone)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH is a major stimulator of 1&alpha;-hydroxylase, the enzyme responsible for converting 25-hydroxyvitamin D to the active form 1,25-dihydroxyvitamin D (calcitriol) in the kidneys. This process is crucial for calcium homeostasis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Calcium:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;High calcium levels actually suppress 1&alpha;-hydroxylase activity,&nbsp;decreasing calcitriol production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. FGF-23:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;FGF-23 also suppresses 1&alpha;-hydroxylase activity and reduces calcitriol levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 1,25 (OH)2D (Calcitriol):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Calcitriol acts through a negative feedback loop to inhibit its own production by suppressing 1&alpha;-hydroxylase.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D basics: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cutaneous production of cholecalciferol is reduced by melanin and sunblocks.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">25 (OH)D [calcidiol] is the major circulating form (formed in the liver by 25 hydroxylase). t1/2 </span><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 2-3 weeks (88% of 25 (OH)D is bound to Vitamin D binding protein)</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2nd hydroxylation occurs in kidney (PCT) by 1&alpha;-hydroxylase forming 1,25 (OH)2D (Calcitriol) &ndash; the active from. 1&alpha;-hydroxylase is hormonally regulated &ndash;</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><em><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Stimulated by:</span></u></em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PTH and low phosphate.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><em><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibited by:</span></u></em><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Ca, FGF-23 &amp; 1,25 (OH)2D (Calcitriol).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1&alpha;-hydroxylase is also present in other cells (keratinocytes, placenta, macrophages), but not hormonally regulated.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inactivation of vitamin D metabolites occurs through 24-hydroxylation.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Actions of 1,25(OH)2D [calcitriol]:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VDR forms heterodimer with retinoid X receptor, inducing target gene expression.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">VDR is expressed in various cells and tissues. Effects of VDR -</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestine: Increased calcium absorption by inducing calbindin 9K, TRPV5, TRPV6. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bone: Regulates osteoblasts (increases osteocalcin, osteopontin, RANKL and FGF23).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parathyroid: Reduces PTH production. </span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Others: Antiproliferative effects (keratinocytes, breast ca cells, prostate ca cells).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Effects of VDR on hair follicle is ligand (Vitamin D) independent!!</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PTH (Parathyroid Hormone) stimulates the production of 1,25(OH)2D (Calcitriol) by activating 1&alpha;-hydroxylase in the kidneys.</span></span></span></p>",
      "correct_choice_id": 215561,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53993,
      "choices": [
        {
          "id": 215441,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">BRAF mutation is the most common genetic alteration </span></span></span></p>"
        },
        {
          "id": 215442,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node micrometastases indicates poor prognosis. </span></span></span></p>"
        },
        {
          "id": 215443,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">It has a propensity to spread via the lymphatic system. </span></span></span></p>"
        },
        {
          "id": 215444,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC is present in up to 25% of thyroid glands at autopsy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 30-year-old man is diagnosed with papillary thyroid carcinoma (PTC). Which of the following statements is not true? </span></span></span></p>",
      "unique_key": "Q6925417",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368785,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Lymph node micrometastases indicates poor prognosis.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC usually spreads primarily via lymphatic system. Lymph node involvement is prognostic but micro metastases (&lt; 2 mm) does not alter prognosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. BRAF mutation is the most common genetic alteration:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> True. a. BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. It has a propensity to spread via the lymphatic system:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is true. PTC has a tendency to spread to the lymph nodes in the neck.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. PTC is present in up to 25% of thyroid glands at autopsy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true. Many people have small, microscopic PTCs that never cause any problems. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary if important thyroid cancers: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTC:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Most common type of thyroid cancer (80-85% of differentiated thyroid cancers)</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetics: RET/PTC rearrangements (20-40%), <em>BRAF V600E mutation (most common),</em> RAS mutations (20-30%).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ol style=\"list-style-type:lower-alpha; margin-left:80px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">BRAF V600E mutations reduce uptake of RAI and increase risk of recurrence (but effect on overall outcomes in unclear).</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Microscopic PTC is found in </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">25% of autopsy thyroids (clinically insignificant).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Characteristic cytological features: Orphan Annie eye appearance with Nuclear grooves and Prominent nucleoli.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Tall cell, columnar cell, hobnail, poorly differentiated &ndash; aggressive variants.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Can be multifocal &amp; invade locally within the thyroid gland/ adjacent structures.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Usually Spreads primarily via lymphatic system.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Slow growth can lead to a significant burden of pulmonary metastases with few symptoms.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node involvement is prognostic but micro metastases (&lt; 2 mm) does not alter prognosis. Most PTCs are identified in early stages (I or II) with excellent prognosis. Stage IV disease has markedly increased mortality but is rare (~1%).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">FTC:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> more common in iodine-deficient regions.</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetics: RAS mutations, PAX8-PPAR&gamma;1 rearrangement.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Diagnosis: Difficult by FNA alone, requires Bx to assess capsular/vascular invasion.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Prognosis: </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<ol style=\"list-style-type:lower-alpha; margin-left:80px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Capsular invasion only: Low risk of metastasis, lobectomy suffices. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Angioinvasive FTC: More aggressive, can metastasize to bone, lung, and CNS.</span></span></span></li>\r\n</ol>\r\n\r\n<ul style=\"list-style-type:circle; margin-left:40px\">\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Higher mortality than PTC, partly due to more frequent stage IV presentation.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Poor Prognostic Factors: Distant metastases, age &gt;55 years, primary tumor size &gt;4 cm, marked vascular invasion.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Lymph node micrometastases (&lt;2 mm) in papillary thyroid carcinoma (PTC) do not alter prognosis, even though lymph node involvement is prognostic.</span></span></span></p>",
      "correct_choice_id": 215442,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53996,
      "choices": [
        {
          "id": 215453,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypernatremia </span></span></span></p>"
        },
        {
          "id": 215454,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypocalcemia </span></span></span></p>"
        },
        {
          "id": 215455,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hyperphosphatemia </span></span></span></p>"
        },
        {
          "id": 215456,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypophosphatemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 60-year-old man with chronic alcoholism was started in IV dextrose. He develops cardiac arrhythmias, seizures, and rhabdomyolysis. Which of the following electrolyte disturbances is most likely responsible for her clinical deterioration?</span></span></p>",
      "unique_key": "Q3089794",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368789,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Hypophosphatemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s clinical presentation is consistent with refeeding syndrome, a potentially life-threatening condition that can occur in severely malnourished individuals after reintroducing nutrition. Refeeding syndrome is characterized by shifts in fluids and electrolytes, with hypophosphatemia being the most prominent and dangerous abnormality.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypophosphatemia can lead to a range of complications, including:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiac arrhythmias:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to impaired myocardial function and energy metabolism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Seizures:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to altered neuronal excitability and cerebral energy depletion.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rhabdomyolysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to muscle cell breakdown from insufficient energy production.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hypernatremia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypernatremia (high sodium) is not a typical feature of refeeding syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Hypocalcemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypocalcemia (low calcium) can occur in refeeding syndrome, but it is less common and less severe than hypophosphatemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hyperphosphatemia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hyperphosphatemia (high phosphate) is the opposite of what is seen in refeeding syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Refeeding syndrome, commonly occurring in severely malnourished individuals after reintroducing nutrition, is characterized by hypophosphatemia, which can lead to cardiac arrhythmias, seizures, and rhabdomyolysis.</span></span></span></p>",
      "correct_choice_id": 215456,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53973,
      "choices": [
        {
          "id": 215361,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid dyshormonogenesis is the most common cause. </span></span></span></p>"
        },
        {
          "id": 215362,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most infants appear normal at birth. </span></span></span></p>"
        },
        {
          "id": 215363,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The recommended initial dose of levothyroxine is 10-15 &micro;g/kg/day. </span></span></span></p>"
        },
        {
          "id": 215364,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Early treatment can significantly improve neurodevelopmental outcomes.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following statements is false regarding congenital hypothyroidism?</span></span></p>",
      "unique_key": "Q7376021",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368771,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) Thyroid dyshormonogenesis is the most common cause. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most common cause is thyroid gland dysgenesis (65%), followed by Thyroid dyshormonogenesis (30%), and TSH-R antibody mediated (5%). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Most infants appear normal at birth. Permanent neurologic damage results if treatment is delayed. Cardiac problems are 4x more in congenital hypothyroidism. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Most infants appear normal at birth:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> The majority of infants appear normal at birth (but classic features are prolonged jaundice, poor feeding, hypotonia, macroglossia, delayed bone maturation, and umbilical hernia). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. The recommended initial dose of levothyroxine is 10-15 &micro;g/kg/day:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> When the diagnosis is confirmed, T4 is instituted at a dose of 10&ndash;15 &mu;g/kg/day and the dose is adjusted by close monitoring of TSH levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Early treatment can significantly improve neurodevelopmental outcomes:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Early treatment with T4 results in normal IQ levels, but subtle neurodevelopmental abnormalities may occur in those with the most severe hypothyroidism at diagnosis or when treatment is delayed or suboptimal.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyroid gland dysgenesis, not thyroid dyshormonogenesis, is the most common cause of congenital hypothyroidism.</span></span></p>",
      "correct_choice_id": 215361,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19921,
      "choices": [
        {
          "id": 79645,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenal hyperplasia</span></span></span></p>"
        },
        {
          "id": 79646,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Unilateral adrenal adenoma</span></span></span></p>"
        },
        {
          "id": 79647,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenocortical carcinoma </span></span></span></p>"
        },
        {
          "id": 79648,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 38-year-old woman with resistant hypertension and muscle weakness has a serum potassium of 2.8 mEq/L. Her plasma renin activity (PRA) is very low and her aldosterone levels are elevated. What is the most common cause?</span></span></p>",
      "unique_key": "Q6447458",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368763,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Bilateral adrenal hyperplasia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of resistant hypertension, hypokalemia, low PRA, and elevated aldosterone is highly suggestive of primary aldosteronism. Among the causes of primary aldosteronism, bilateral adrenal hyperplasia is the most common, accounting for approximately 60-70% of cases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Unilateral adrenal adenoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While a common cause of primary aldosteronism, it is less frequent than bilateral adrenal hyperplasia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Adrenocortical carcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare cause of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Pheochromocytoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a tumor of the adrenal medulla that secretes catecholamines. It is not associated with the typical findings of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral adrenal hyperplasia is the most common cause of primary aldosteronism, accounting for 60-70% of cases. It leads to elevated aldosterone and low plasma renin activity, causing hypertension and hypokalemia.</span></span></span></p>",
      "correct_choice_id": 79645,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19918,
      "choices": [
        {
          "id": 79633,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling. </span></span></span></p>"
        },
        {
          "id": 79634,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High dose Dexamethasone suppression test. </span></span></span></p>"
        },
        {
          "id": 79635,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CRH stimulation test. </span></span></span></p>"
        },
        {
          "id": 79636,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI of the pituitary.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the gold standard to differentiate Cushing&#39;s disease (ACTH-producing pituitary adenoma) from ectopic Cushing&#39;s syndrome?</span></span></p>",
      "unique_key": "Q5586498",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368761,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Inferior petrosal sinus sampling.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling (IPSS) is the gold standard test to differentiate between Cushing&#39;s disease and ectopic ACTH syndrome. This involves measuring ACTH levels in blood samples taken from the inferior petrosal sinuses (which drain the pituitary gland) and a peripheral vein before and after administration of CRH. A central-to-peripheral ACTH ratio greater than 2 at baseline or greater than 3 after CRH stimulation is indicative of Cushing&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. High dose Dexamethasone suppression test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this test can help distinguish between different causes of Cushing&#39;s syndrome, it is not as specific as IPSS in differentiating pituitary from ectopic ACTH secretion. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cortisol suppression &gt;50% after q6h 2 mg DEX for 2 days is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CRH stimulation test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test can be helpful in the evaluation of Cushing&#39;s syndrome, but it is not the gold standard for differentiating between pituitary and ectopic sources of ACTH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ACTH increase &gt;40% at 15&ndash;30 min + cortisol increase &gt;20% at 45&ndash;60 min after CRH 100 &mu;g IV is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. MRI of the pituitary:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> MRI can detect pituitary tumors, but not all ACTH-producing tumors are visible on MRI. Additionally, incidental pituitary lesions can be found in patients without Cushing&#39;s disease. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the presence of cortisol &amp; ACTH excess, a lesion &gt; 6 mm is suggestive of Cushing&rsquo;s disease.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inferior petrosal sinus sampling (IPSS) is the gold standard for differentiating Cushing&#39;s disease from ectopic ACTH syndrome by measuring ACTH levels from the inferior petrosal sinuses and comparing them with peripheral levels after CRH administration.</span></span></span></p>",
      "correct_choice_id": 79633,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53987,
      "choices": [
        {
          "id": 215417,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Associated with URI. </span></span></span></p>"
        },
        {
          "id": 215418,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Elevated ESR. </span></span></span></p>"
        },
        {
          "id": 215419,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Positive anti-TPO.</span></span></span></p>"
        },
        {
          "id": 215420,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Giant cells in biopsy.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 35-year-old woman presents with a one-week history of fever, neck pain, and fatigue. On physical examination, her thyroid gland is tender. Thyroid function tests reveal elevated free T4 and suppressed TSH. Which of the following statements regarding her underlying condition is FALSE?</span></span></p>",
      "unique_key": "Q8596929",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368781,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. C) Positive anti-TPO. </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The diagnosis is subacute (granulomatous) thyroiditis (a.k.a De Quervain&rsquo;s thyroiditis). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Disease usually follows an URI and has a classic triphasic course (thyrotoxic </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> hypothyroid </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> resolution). ESR usually elevated and RAIU will be suppressed. TPO antibodies will usually test negative and biopsy typically shows patchy inflammation with granulomas and giant cells. Treatment is supportive (NSAIDs 1st line </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:Wingdings\">&rarr;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Prednisolone in case of poor response).</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Beta blockers can be used to abate thyrotoxic symptoms and anti-thyroid drugs have NO role. LT4 replacement may be needed if the hypothyroid phase is prolonged, but doses should be low enough (50&ndash;100 &mu;g/d) to allow TSH-mediated recovery. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option </span></strong><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A. Associated with URI:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a true statement, as De Quervain&rsquo;s thyroiditis is often triggered by a viral infection.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Elevated ESR:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true due to the inflammatory process.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Giant cells in biopsy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is the characteristic histological finding due to the presence of granulomas in De Quervain&rsquo;s thyroiditis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid peroxidase (TPO) antibodies are usually negative in subacute (De Quervain&rsquo;s) thyroiditis, which is associated with an elevated ESR and giant cells in biopsy following an upper respiratory infection.</span></span></span></p>",
      "correct_choice_id": 215419,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54026,
      "choices": [
        {
          "id": 215573,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN1 </span></span></span></p>"
        },
        {
          "id": 215574,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 </span></span></span></p>"
        },
        {
          "id": 215575,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CASR</span></span></span></p>"
        },
        {
          "id": 215576,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GCM2</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following genetic mutations is usually associated with parathyroid carcinoma?</span></span></span></p>",
      "unique_key": "Q9771638",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368743,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) HRPT2</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 (CDC73) is a tumor suppressor gene. Inactivating mutations in both copies of this gene are found in the majority of parathyroid carcinomas. These mutations lead to the loss of parafibromin, a protein that normally helps regulate cell growth and division.</span></span></span></p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 mutations are also associated HPT-JT (Hyperparathyroidism-Jaw tumour). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. MEN1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene are associated with multiple endocrine neoplasia type 1 (MEN1),&nbsp;a syndrome that can include parathyroid adenomas but rarely carcinoma.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CASR:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene cause familial hypocalciuric hypercalcemia (FHH),&nbsp;a benign condition unrelated to parathyroid cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. GCM2:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Mutations in this gene are associated with <em><u>non-syndromic</u></em> familial isolated hyperparathyroidism (FIHP),&nbsp;which is characterized by benign parathyroid tumors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">HRPT2 mutations are usually associated with parathyroid carcinoma.</span></span></p>",
      "correct_choice_id": 215574,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53971,
      "choices": [
        {
          "id": 215353,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Graves disease </span></span></span></p>"
        },
        {
          "id": 215354,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyrotoxicosis factitia </span></span></span></p>"
        },
        {
          "id": 215355,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Toxic Multinodular Goiter </span></span></span></p>"
        },
        {
          "id": 215356,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroiditis</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman presents with a 2-week history of palpitations and excessive sweating. Physical examination reveals a non-tender thyroid gland. Thyroid function tests show an elevated free T4 and suppressed TSH. Radioactive iodine uptake (RAIU) scan is shown. Thyroglobulin levels are low. What is the likely diagnosis?</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/screenshot-2024-08-17-133042_3j62nY0.jpg\" style=\"height:233px; width:450px\" /></span></span></p>",
      "unique_key": "Q6218190",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368770,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Thyrotoxicosis factitia.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The low RAIU and low thyroglobulin levels in case of thyrotoxicosis confirm that the thyroid gland is not producing excess hormone. Hence, the diagnosis of thyrotoxicosis factitial (exogenous thyroid hormone use).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Graves&#39; disease:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Graves&#39; disease is an autoimmune condition causing hyperthyroidism. It typically presents with a diffuse goiter, increased RAIU, and high thyroglobulin levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Toxic Multinodular Goiter:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This condition also has an increased RAIU and increased thyroglobulin levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> RAIU can be suppressed but thyroglobulin levels are usually elevated in thyroiditis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thyrotoxicosis factitia is characterized by low radioactive iodine uptake (RAIU) and low thyroglobulin levels, indicating exogenous thyroid hormone use.</span></span></p>",
      "correct_choice_id": 215354,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "ImageBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 39116,
      "choices": [
        {
          "id": 156199,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cushing&#39;s syndrome </span></span></span></p>"
        },
        {
          "id": 156200,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conn&#39;s syndrome </span></span></span></p>"
        },
        {
          "id": 156201,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liddle&#39;s syndrome </span></span></span></p>"
        },
        {
          "id": 156202,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Connshing syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old patient presents with dizziness. On examination, his BP is 180/110 mm Hg, and he has stretch marks in the trunk. His blood reports show a serum potassium (S. Potassium) of 2.7 mEq/L and HCO3- of 31 mEq/L. He also has elevated aldosterone levels, and after a dexamethasone suppression test, his serum cortisol was 60 nmol/L. What is the likely diagnosis?</span></span></span></p>",
      "unique_key": "Q4921804",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368758,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Connshing syndrome</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient has <strong>Hypertension, Hypokalemia, Metabolic alkalosis </strong>and elevated aldosterone confirming mineralocorticoid excess (Conn&rsquo;s syndrome). The presence of stretch marks and high cortisol (&gt; 50 nmol/L) after dexamethasone indicates cortisol excess (Cushing&rsquo;s syndrome).</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Some patients with Conn&rsquo;s syndrome can also have mild autonomous cortisol secretion &ndash; called as &lsquo;Connshing&rsquo; syndrome. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Cushing&#39;s syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Even though patient has features of Cushing&rsquo;s syndrome, he also has elevated aldosterone, hence it is not the accurate diagnosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:Calibri,sans-serif\"><strong>Option B.</strong>&nbsp;</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><strong>Conn&rsquo;s syndrome</strong>: Even though patient has features of Conn&rsquo;s syndrome, he also has elevated cortisol, hence it is not the accurate diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Liddle&#39;s syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a rare genetic disorder causing similar electrolyte abnormalities but with normal or low aldosterone levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The combination of features indicating both Conn&#39;s syndrome (mineralocorticoid excess with hypertension, hypokalemia, and metabolic alkalosis) and Cushing&#39;s syndrome (elevated cortisol levels after dexamethasone suppression) points towards Connshing syndrome, where both aldosterone and cortisol are elevated.</span></span></span></p>",
      "correct_choice_id": 156202,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53946,
      "choices": [
        {
          "id": 215253,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">S. Calcium at 11 years </span></span></span></p>"
        },
        {
          "id": 215254,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate total thyroidectomy </span></span></span></p>"
        },
        {
          "id": 215255,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Plasma metanephrines at 16 years </span></span></span></p>"
        },
        {
          "id": 215256,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI pituitary at 5 years</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A couple comes for counseling regarding their newborn&#39;s health. The father of the child had an MTC, was operated on recently, and was known to have a RET codon 918 mutation. The newborn has been screened and carries the same mutation as well. What will be your advice regarding the newborn?</span></span></p>",
      "unique_key": "Q7092955",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368751,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Immediate total thyroidectomy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The RET codon 918 mutation is associated with Multiple Endocrine Neoplasia type 2B (MEN2B), which carries a very high risk of early-onset and aggressive medullary thyroid carcinoma (MTC). Prophylactic total thyroidectomy is recommended in the first year of life, ideally within the first 6 months, to prevent the development of MTC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-180531.png\" style=\"height:418px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. S. Calcium at 11 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Recommended for RET codon 634 or 883 mutations, where hyperparathyroidism is common. Hyperparathyroidism is not a feature of codon 918 mutations, hence screening is NOT recommended. For mutations other than For 663, 883 and 918 &ndash; screening can be started at 16 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Plasma metanephrines at 16 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Recommended for screening of pheochromocytoma for RET codon mutations (other than 663, 883 and 918). For 663, 883 and 918 mutations &ndash; screening should be started at 11 years. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. MRI pituitary at 5 years:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the recommendations for screening pituitary tumors in case of MEN1. Pituitary tumors are not associated with MEN2B. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate total thyroidectomy is recommended for newborns with RET codon 918 mutation to prevent medullary thyroid carcinoma (MTC).</span></span></span></p>",
      "correct_choice_id": 215254,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53983,
      "choices": [
        {
          "id": 215401,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">RAI therapy is ineffective in young patients. </span></span></span></p>"
        },
        {
          "id": 215402,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient is experiencing a relapse of Graves&#39; disease.</span></span></span></p>"
        },
        {
          "id": 215403,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient is developing hypothyroidism.</span></span></span></p>"
        },
        {
          "id": 215404,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The full effect of RAI therapy takes 2-3 months to manifest.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 25-year-old woman with Graves&#39; disease undergoes RAI therapy. Two months later, she complains of persistent palpitations and heat intolerance. Which of the following is the most likely explanation for her persistent symptoms?</span></span></p>",
      "unique_key": "Q4854169",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368778,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) The full effect of RAI therapy takes 2-3 months to manifest.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">It can take several weeks to months for RAI to fully destroy thyroid tissue and for symptoms to resolve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">. <strong>RAI therapy is ineffective in young patients:</strong> RAI is effective in all age groups.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">. <strong>The patient is experiencing a relapse of Graves&#39; disease:</strong> Relapse is possible, but less likely within two months.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">.<strong> The patient is developing hypothyroidism:</strong> &nbsp;Hypothyroidism is a later complication of RAI.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary of RAIA in Graves:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Indication</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Initial treatment or for relapses after antithyroid drugs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Tracer used:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> I131. Emits &beta; &amp; &gamma;. t1/2 </span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Cambria Math&quot;,serif\">&sim;</span></span><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> 8 days. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Elderly/Cardiac Patients:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Consider pretreatment with antithyroid drugs and beta-blockers (because of small, increased risk of Thyrotoxic Crisis)</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Carbimazole/Methimazole: Stop 2-3 days before and restart 3-7 days after RAI.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">PTU: Prolonged radioprotective effect, requires longer discontinuation or higher RAI dose.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Persistence of Hyperthyroidism:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Can persist for 2-3 months, managed with beta-blockers or antithyroid drugs.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Safety Precautions:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Avoid close contact with children and pregnant women for 5-7 days.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Complications: </span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radiation Thyroiditis: Mild pain may occur 1-2 weeks after treatment.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Flare of Orbitopathy: Especially in smokers. Consider prednisone pre-treatment.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Permanent Hypothyroidism: Risk is 10-20% in the first year, 5% per year thereafter, requiring lifelong LT4 replacement.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Possibly a small increased lifetime risk of solid cancers. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Contraindications:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Pregnancy, breastfeeding and suspected thyroid cancer. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The full effect of RAI therapy for Graves&#39; disease takes 2-3 months to manifest, which can explain persistent symptoms shortly after treatment.</span></span></p>",
      "correct_choice_id": 215404,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53960,
      "choices": [
        {
          "id": 215309,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45X/46XY </span></span></span></p>"
        },
        {
          "id": 215310,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45X/46XX </span></span></span></p>"
        },
        {
          "id": 215311,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">45XY/45XXY </span></span></span></p>"
        },
        {
          "id": 215312,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">46XX/46XY</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the karyotype most commonly associated with mixed gonadal dysgenesis (MGD)?</span></span></p>",
      "unique_key": "Q2629617",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368755,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 45X/46XY</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mixed gonadal dysgenesis (MGD) is characterized by the presence of both testicular and ovarian tissue in an individual. The most common karyotype associated with MGD is 45, X/46, XY mosaicism. This means that some cells in the body have a missing X chromosome (45, X), while others have the typical male karyotype (46, XY). The degree of mosaicism and the distribution of the different cell lines can vary greatly, leading to a wide range of phenotypic presentations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most are assigned as males and may have asymmetry (streak gonad and hemiuterus on one side, dysgenetic testis and hemiscrotum on the other). </span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased risk of germ cell cancer (up to 35% in intraabdominal gonads) &ndash; so prophylactic removal of intrabdominal gonads is warranted. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 45X/46XX:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype is associated with Turner mosaics. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 45XY/45XXY:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype combination is seen in Klinefelter mosaics. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 46XX/46XY:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This karyotype may be seen in Ovotesticular DSD (but most common is 46XX).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most common karyotype associated with mixed gonadal dysgenesis is 45,X/46,XY.</span></span></span></p>",
      "correct_choice_id": 215309,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53979,
      "choices": [
        {
          "id": 215385,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Age &lt; 50 is a risk factor</span></span></span></p>"
        },
        {
          "id": 215386,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Long-term anticoagulation is unnecessary </span></span></span></p>"
        },
        {
          "id": 215387,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Digoxin sensitivity is increased</span></span></span></p>"
        },
        {
          "id": 215388,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Warfarin sensitivity is decreased</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient with thyrotoxicosis develops atrial fibrillation. Which of the following statements regarding their management is CORRECT?</span></span></p>",
      "unique_key": "Q5503350",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368776,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Long-term anticoagulation is unnecessary </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Anticoagulation should be considered in all patients with AF and thyrotoxicosis. There is often spontaneous reversion to sinus rhythm with control of hyperthyroidism, and long-term anticoagulation is not usually required. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Decreased warfarin doses are required when patients are thyrotoxic (sensitivity increased as production of vitamin K dependent clotting factors are reduced).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">If digoxin is used, increased doses are often needed in the thyrotoxic state (sensitivity decreased because of increased renal clearance and increased number of Na-K ATPse)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Age &lt; 50 is a risk factor:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Elderly patients (Age &gt;50) are at increased risk.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Digoxin sensitivity is increased:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Digoxin sensitivity is decreased because of increased renal clearance and increased number of Na-K ATPse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Warfarin sensitivity is decreased:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Warfarin sensitivity is increased as production of vitamin K dependent clotting factors are reduced.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Long-term anticoagulation is generally unnecessary in patients with atrial fibrillation and thyrotoxicosis, as spontaneous reversion to sinus rhythm often occurs with control of hyperthyroidism.</span></span></p>",
      "correct_choice_id": 215386,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19937,
      "choices": [
        {
          "id": 79709,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Diabetic dermopathy </span></span></span></p>"
        },
        {
          "id": 79710,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Necrobiosis lipoidica diabeticorum </span></span></span></p>"
        },
        {
          "id": 79711,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Lichen planus </span></span></span></p>"
        },
        {
          "id": 79712,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Scleredema</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man with long-standing diabetes presents with the lesion shown in the image. Identify the condition:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/20/screenshot-2024-08-20-093055.png\" style=\"height:217px; width:300px\" /></span></span></p>",
      "unique_key": "Q9121333",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368779,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) Diabetic dermopathy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The image shows multiple, well-defined, hyperpigmented atrophic macules over both shins, which is characteristic of diabetic dermopathy. Diabetic dermopathy, also known as shin spots, is the most common cutaneous manifestation of diabetes mellitus. It is caused by changes in the small blood vessels of the skin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Necrobiosis lipoidica diabeticorum:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition presents as larger,&nbsp;yellowish-brown patches with a raised,&nbsp;reddish border,&nbsp;often located on the shins.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Lichen planus:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This inflammatory skin condition presents as purple,&nbsp;itchy,&nbsp;flat-topped bumps.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Scleredema:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This condition is characterized by thickening and hardening of the skin,&nbsp;usually on the back or neck.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Diabetic dermopathy, characterized by hyperpigmented atrophic macules over the shins, is the most common cutaneous manifestation of diabetes.</span></span></span></p>",
      "correct_choice_id": 79709,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19927,
      "choices": [
        {
          "id": 79669,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Radiodensity &gt; 20 HU </span></span></span></p>"
        },
        {
          "id": 79670,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Size &ge; 4cm </span></span></span></p>"
        },
        {
          "id": 79671,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Elevated steroid precursors in urine </span></span></span></p>"
        },
        {
          "id": 79672,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcifications in the adrenal gland</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 54-year-old man presents with an incidental 6 cm adrenal lesion with a radiodensity of 45 HU. Which of the following is NOT predictive of adrenocortical cancer (ACC)?</span></span></p>",
      "unique_key": "Q8858234",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368769,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Calcifications in adrenal gland</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">While calcifications can be present in adrenal lesions, they are more commonly associated with benign lesions like adrenal adenomas. The presence of calcifications does not necessarily predict malignancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Radiodensity &gt; 20 HU:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenocortical carcinomas typically have higher radiodensity on unenhanced CT scans (&gt;20 HU) due to their lower fat content.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Size &ge; 4 cm:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Larger adrenal lesions are more likely to be malignant. A 6 cm lesion is highly suspicious for ACC.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Elevated steroid precursors in urine:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenocortical carcinomas often produce excess steroid precursors, which can be detected in urine. This is a suggestive feature of malignancy.</span></span></span><br />\r\n&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A recently introduced diagnostic test, urine steroid metabolomics, has a 2x higher PPV than imaging in detecting ACC, based on a distinct &ldquo;steroid fingerprint&rdquo; with accumulating precursor steroids in 24-h urine.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Calcifications can be present in adrenal lesions but are more commonly associated with benign lesions like adrenal adenomas and do not necessarily predict malignancy.</span></span></span></p>",
      "correct_choice_id": 79672,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53969,
      "choices": [
        {
          "id": 215345,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Levothyroxine 200&micro;g IV STAT</span></span></span></p>"
        },
        {
          "id": 215346,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Hydrocortisone 100mg IV STAT</span></span></span></p>"
        },
        {
          "id": 215347,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Give Levothyroxine 200&micro;g and 100mg Hydrocortisone IV STAT</span></span></span></p>"
        },
        {
          "id": 215348,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Observation and repeat TFT after discharge</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 68-year-old male presents with congestive heart failure and sepsis. Thyroid function tests (TFT) reveal a low total T3, normal free T4 and normal TSH. What is the next step? </span></span></p>",
      "unique_key": "Q3300920",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368768,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. D) Observation and repeat TFT after discharge</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s presentation of low total T3, normal free T4, and normal TSH in the setting of congestive heart failure and sepsis is most consistent with <strong>sick euthyroid syndrome (SES)</strong>. SES is a common finding in critically ill patients and is characterized by alterations in thyroid hormone levels without underlying thyroid disease (a.k.a Non Thyroidal Illness)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">In SES, the conversion of T4 to T3 is often impaired, leading to low T3 levels. However, TSH and free T4 levels are usually normal, as seen in this case.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Management of SES:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Observation and treat the underlying condition. Can repeat TFTs after recovery from illness if suspicious of underlying thyroid dysfunction. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Give Levothyroxine 200&micro;g IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Levothyroxine replacement is not indicated in SES and may even be harmful.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. Give Hydrocortisone 100mg IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This could be appropriate for suspected adrenal insufficiency. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Give Levothyroxine 200&micro;g and 100mg Hydrocortisone IV STAT:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This could be an appropriate treatment for myxedema coma. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">In patients with sick euthyroid syndrome, characterized by low total T3, normal free T4, and normal TSH in the context of critical illness, observation and repeat TFTs after recovery is the appropriate management.</span></span></span></p>",
      "correct_choice_id": 215348,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19922,
      "choices": [
        {
          "id": 79649,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Liddle syndrome </span></span></span></p>"
        },
        {
          "id": 79650,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gordon syndrome (PHA2) </span></span></span></p>"
        },
        {
          "id": 79651,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gitelman syndrome </span></span></span></p>"
        },
        {
          "id": 79652,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Apparent mineralocorticoid excess (SAME)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old man presents with severe hypertension, hypokalemia, and metabolic alkalosis. His brother died of intracranial hemorrhage (ICH) at the age of 12. His plasma renin and aldosterone levels are low, and his blood pressure normalized after adding spironolactone. Which of the following is the most likely diagnosis?</span></span></p>",
      "unique_key": "Q7976445",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368764,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Apparent mineralocorticoid excess (SAME)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAME is an autosomal recessive disorder caused by a deficiency of 11&beta;-hydroxysteroid dehydrogenase type 2 (11&beta;-HSD2), which normally inactivates cortisol to cortisone. In SAME, cortisol acts as a potent mineralocorticoid, leading to sodium retention, potassium excretion, and hypertension.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The positive response to spironolactone, a mineralocorticoid receptor antagonist, further supports the diagnosis of SAME, as it blocks the mineralocorticoid receptor, mitigating the effects of cortisol.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Liddle syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Response to spironolactone would be poor. Patients typically respond to amiloride (as this disorder is due to hyperfunctioning ENaC channels in the principal cells).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Gordon syndrome (PHA2):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Response to spironolactone would be poor and patients usually present with hypertension, hyperkalemia and metabolic acidosis. Patients typically respond to thiazides (as this disorder is due to hyperfunctioning Na-Cl transporters in the DCT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Gitelman syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This syndrome can cause hypokalemia and metabolic alkalosis, but patients tend to be normotensive and renin/aldosterone levels would be elevated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">SAME is caused by a deficiency of 11&beta;-hydroxysteroid dehydrogenase type 2, leading to cortisol acting as a potent mineralocorticoid. The patient&#39;s response to spironolactone supports this diagnosis.</span></span></span></p>",
      "correct_choice_id": 79652,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54019,
      "choices": [
        {
          "id": 215545,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab </span></span></span></p>"
        },
        {
          "id": 215546,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teplizumab </span></span></span></p>"
        },
        {
          "id": 215547,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Teprotumumab </span></span></span></p>"
        },
        {
          "id": 215548,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Atezolizumab</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following monoclonal antibodies has been approved for X-linked hypophosphatemia (XLH)?</span></span></p>",
      "unique_key": "Q5744026",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368740,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Burosumab</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab is a monoclonal antibody that targets and inhibits fibroblast growth factor 23 (FGF23). Excess FGF23 is the primary driver of XLH, causing renal phosphate wasting and impaired bone mineralization. By inhibiting FGF23, burosumab can effectively increase serum phosphate levels, improve bone mineralization, and alleviate symptoms associated with XLH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab also have shown promise in TIO (tumor induced osteoamalacia) &ndash; which also occurs due to production of FGF-23 by certain tumours. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Teplizumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (CD3) is used in the treatment of type 1 diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Teprotumumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (IGF-1r) is used in the treatment of thyroid eye disease (Graves&#39; ophthalmopathy).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Atezolizumab:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;This monoclonal antibody (PD-L1) is used in the treatment of certain types of cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Burosumab is a monoclonal antibody approved for X-linked hypophosphatemia (XLH).</span></span></p>",
      "correct_choice_id": 215545,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19924,
      "choices": [
        {
          "id": 79657,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dexamethasone suppression test </span></span></span></p>"
        },
        {
          "id": 79658,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Saline infusion test </span></span></span></p>"
        },
        {
          "id": 79659,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CT scan of the abdomen </span></span></span></p>"
        },
        {
          "id": 79660,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Urinary metanephrines</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old man presents with resistant hypertension&gt; His serum potassium is 3 mEq/L, and his serum HCO3- is 29 mEq/L. His renin levels were low and aldosterone levels were elevated. What is the confirmatory test for the suspected diagnosis?</span></span></p>",
      "unique_key": "Q9366513",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368766,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Saline infusion test</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (resistant hypertension, hypokalemia, metabolic alkalosis, low renin, and high aldosterone) strongly suggests primary aldosteronism. The saline infusion test is the gold standard confirmatory test for primary aldosteronism. In this test, the patient receives a large volume of saline intravenously, and aldosterone levels are measured. Failure of aldosterone to suppress after saline infusion confirms the diagnosis of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Dexamethasone suppression test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose Cushing&#39;s syndrome (excess cortisol production), not primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. CT scan of the abdomen:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This imaging test can help visualize adrenal glands and identify tumors, but it does not confirm the functional diagnosis of primary aldosteronism.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Urinary metanephrines:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to diagnose pheochromocytoma, which is not consistent with the patient&#39;s presentation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The saline infusion test is the confirmatory test for primary aldosteronism. It involves administering saline and measuring aldosterone levels, which should suppress if primary aldosteronism is present.</span></span></span></p>",
      "correct_choice_id": 79658,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19916,
      "choices": [
        {
          "id": 79625,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKAR1A </span></span></span></p>"
        },
        {
          "id": 79626,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 </span></span></span></p>"
        },
        {
          "id": 79627,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">GNAS1 </span></span></span></p>"
        },
        {
          "id": 79628,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PRKACA</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the most common mutation found in ACTH-secreting pituitary adenomas?</span></span></p>",
      "unique_key": "Q4003198",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368760,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) USP8</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 mutations are the most frequent genetic alterations found in ACTH-secreting pituitary adenomas, responsible for Cushing&#39;s disease. These mutations lead to increased deubiquitination of the epidermal growth factor receptor (EGFR), resulting in its stabilization and activation. This in turn promotes the synthesis and secretion of ACTH, leading to the development of Cushing&#39;s disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. PRKAR1A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Mutations in this gene are associated with Carney complex, which is usually associated with PPNAD (Primary pigmented Nodular Adrenal Disease).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. GNAS1:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Activating mutations in this gene can result in McCune-Albright syndrome (MAS). Cushing&rsquo;s syndrome in MAS is usually ACTH independent. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PRKACA:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mutations in this gene are found in a subset (40%) of cortisol-producing adrenal adenomas and are not typically associated with ACTH-secreting pituitary adenomas.</span></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Another mutation in a tumor suppressor gene ARMC5 have been identified as a prevalent cause of Cushing&rsquo;s due to bilateral macronodular adrenal hyperplasia. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">USP8 mutations are the most frequent genetic alterations found in ACTH-secreting pituitary adenomas, leading to increased deubiquitination and stabilization of the EGFR, which promotes ACTH synthesis and secretion.</span></span></span></p>",
      "correct_choice_id": 79626,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53943,
      "choices": [
        {
          "id": 215241,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers </span></span></span></p>"
        },
        {
          "id": 215242,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Intestinal dysfunction </span></span></span></p>"
        },
        {
          "id": 215243,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mutation in cysteine-rich domain of RET </span></span></span></p>"
        },
        {
          "id": 215244,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common mutation is RET codon 918</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is NOT a feature of MEN2B?</span></span></p>",
      "unique_key": "Q8529181",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368750,
      "difficulty_level": "difficult",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Mutation in cysteine-rich domain of RET</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2B (Multiple Endocrine Neoplasia type 2B) is characterized by (M&rsquo;s):</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullary thyroid carcinoma (MTC)</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pheochromocytoma</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucosal neuromas</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Marfanoid habitus</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Medullated corneal nerve fibers</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Megacolon due to Intestinal ganglioneuromatosis</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Most common mutation is RET codon 918</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (M918T) in the tyrosine kinase domain of the RET proto-oncogene.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Medullated corneal nerve fibers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a distinctive feature of MEN2B.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Intestinal dysfunction:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a common feature due to intestinal ganglioneuromatosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Most common mutation is RET codon 918:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is the characteristic mutation in MEN2B (seen in 95% cases). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MEN2B is characterized by mutations in the tyrosine kinase domain of RET, not the cysteine-rich domain.</span></span></span></p>",
      "correct_choice_id": 215243,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53935,
      "choices": [
        {
          "id": 215209,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediate surgical removal of the testicular masses </span></span></span></p>"
        },
        {
          "id": 215210,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Start high-dose glucocorticoid therapy </span></span></span></p>"
        },
        {
          "id": 215211,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Initiate testosterone replacement therapy </span></span></span></p>"
        },
        {
          "id": 215212,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Perform a biopsy of the testicular masses to rule out malignancy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old boy with known Congenital Adrenal Hyperplasia (CAH) presents with bilateral testicular masses. His serum ACTH levels are elevated, and ultrasound reveals B/L hypoechoic lesions in the testes. Which of the following is the most appropriate next step?</span></span></p>",
      "unique_key": "Q7709339",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368748,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Start high-dose glucocorticoid therapy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a patient with CAH, bilateral testicular masses with elevated ACTH levels and hypoechoic lesions on ultrasound are highly suggestive of TART (Testicular Adrenal Rest Tissue). These are benign tumors composed of ectopic adrenal tissue that can develop in the testes due to chronic ACTH stimulation. TART can compromise sperm production and induce testicular fibrosis that may be irreversible.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most appropriate next step is to <strong>start high-dose glucocorticoid therapy</strong> to suppress ACTH production and induce regression of the adrenal rest tumors. This is the primary treatment for adrenal rest tumors in CAH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Immediate surgical removal of the testicular masses:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Surgery is not the initial approach for adrenal rest tumors. Medical management with glucocorticoids is usually attempted first.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Initiate testosterone replacement therapy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Testosterone replacement is not indicated for adrenal rest tumors and may even worsen the condition by stimulating further tumor growth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Perform a biopsy of the testicular masses to rule out malignancy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While biopsy can be considered in cases with atypical features or lack of response to glucocorticoids, it is not the most appropriate initial step. Adrenal rest tumors are typically benign, and the clinical presentation and imaging findings strongly suggest this diagnosis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bilateral testicular masses in a patient with congenital adrenal hyperplasia (CAH) are likely due to testicular adrenal rest tumors (TART). High-dose glucocorticoid therapy suppresses ACTH production and induces regression of the tumors.</span></span></span></p>",
      "correct_choice_id": 215210,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54043,
      "choices": [
        {
          "id": 215641,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulinoma </span></span></span></p>"
        },
        {
          "id": 215642,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Factitious hypoglycemia due to sulfonylurea</span></span></span></p>"
        },
        {
          "id": 215643,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Non-insulin-mediated hypoglycemia </span></span></span></p>"
        },
        {
          "id": 215644,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IGF-2 related hypoglycemia</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man presents with recurrent hypoglycemia, confirmed by Whipple&#39;s triad. Laboratory investigations reveal a beta-hydroxybutyrate (&beta;-OHB) level of 5 mmol/L and a poor blood glucose response to glucagon. The most likely diagnosis is:</span></span></p>",
      "unique_key": "Q3868642",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368746,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Non-insulin-mediated hypoglycemia</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels&nbsp;</span></strong><span style=\"font-size:12.0pt\">and&nbsp;<strong>Poor response to glucagon </strong>indicated that the hypoglycemia is not mediated by insulin or insulin like factors (IGF-2). Examples include critical illness, organ failure (liver, kidney), sepsis, counter-regulatory hormone deficiencies (GH/cortisol) etc. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Insulinoma:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This would typically present with suppressed ketone levels due to the inhibitory effect of excess insulin on lipolysis and ketogenesis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Factitious hypoglycemia due to sulfonylurea:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sulfonylureas increase insulin secretion,&nbsp;and hypoglycemia due to these medications would and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of hyperinsulinemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. IGF-2 related hypoglycemia:</span></strong><span style=\"font-size:12.0pt\">&nbsp;This is a rare cause of hypoglycemia and tend to have suppressed &beta;-OHB (&lt; 2.7 mmol/L) in view of insulin like action. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Elevated &beta;-OHB levels and poor response to glucagon indicate non-insulin-mediated hypoglycemia, such as critical illness or organ failure.</span></span></span></p>",
      "correct_choice_id": 215643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19947,
      "choices": [
        {
          "id": 79749,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Discontinue the insulin infusion </span></span></span></p>"
        },
        {
          "id": 79750,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Switch to subcutaneous insulin </span></span></span></p>"
        },
        {
          "id": 79751,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Add dextrose to the intravenous fluids </span></span></span></p>"
        },
        {
          "id": 79752,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Increase the rate of the insulin infusion</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 45-year-old man with type 2 diabetes presents to the emergency department with DKA. His initial blood glucose level is 650 mg/dL. After 6 hours of treatment with intravenous fluids and insulin, his blood glucose drops to 200 mg/dL. Which of the following is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q8201858",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368786,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. C) Add dextrose to the intravenous fluids</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When the blood glucose level drops to 200-250 mg/dL during DKA treatment, it is crucial to add dextrose to the intravenous fluids to prevent hypoglycemia and to maintain a target plasma glucose is 150-200 mg/dL. Insulin infusion can thus, be continued at a lower rate to ensure correction of ketoacidosis. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Discontinue the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin should not be discontinued until the ketoacidosis is resolved,&nbsp;as indicated by a normal anion gap and beta-hydroxybutyrate level.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Switch to subcutaneous insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Subcutaneous insulin is not appropriate in the acute management of DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Increase the rate of the insulin infusion:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Increasing the insulin infusion rate could lead to hypoglycemia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">When blood glucose drops to 200-250 mg/dL during DKA treatment, add dextrose to IV fluids to prevent hypoglycemia and continue insulin infusion.</span></span></span></p>",
      "correct_choice_id": 79751,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19932,
      "choices": [
        {
          "id": 79689,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">3% NaCl </span></span></span></p>"
        },
        {
          "id": 79690,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV fluids </span></span></span></p>"
        },
        {
          "id": 79691,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Insulin infusion </span></span></span></p>"
        },
        {
          "id": 79692,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Potassium supplementation</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">A young woman with type 1 diabetes presents to the emergency department with diabetic ketoacidosis (DKA) after stopping insulin. On examination, she is delirious and initial laboratory reports show:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">S. Na 128 mEq/L, S. K+ 4.3 mEq/L, BUN 76 mg/dL, S. Cr 2.2 mg/dL, S. HCO3- 10 mEq/L, Blood glucose 520 mg/dL. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT an appropriate treatment?</span></span></span></p>",
      "unique_key": "Q4323650",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368774,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) 3% NaCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient presents with pseudohyponatremia, which is a falsely low sodium level due to the presence of hyperglycemia. The corrected sodium level can be calculated using the following formula:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = Measured Sodium + 1.6 mEq/L * (Serum Glucose [mg/dL] - 100 mg/dL) / 100</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In this case, the corrected sodium is:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Corrected Sodium = 128 mEq/L + 1.6 mEq/L * (520 mg/dL - 100 mg/dL) / 100 = 135 mEq/L</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Since the corrected sodium is within the normal range (135-145 mEq/L), administering hypertonic saline (3% NaCl) is not indicated. In fact, it could be harmful by worsening hyperosmolar state. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. 0.9% sodium chloride (NaCl):</span></strong><span style=\"font-size:12.0pt\"> This isotonic fluid is appropriate for rehydration in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Insulin infusion:</span></strong><span style=\"font-size:12.0pt\"> This is essential to lower blood glucose levels and correct ketoacidosis in DKA.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. Potassium supplementation:</span></strong><span style=\"font-size:12.0pt\"> While initial potassium levels are normal, they can drop rapidly with insulin therapy. Therefore, potassium supplementation is often necessary during DKA treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Hypertonic saline (3% NaCl) is not indicated in DKA with pseudohyponatremia; it could worsen the hyperosmolar state.</span></span></span></p>",
      "correct_choice_id": 79689,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53933,
      "choices": [
        {
          "id": 215201,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metformin </span></span></span></p>"
        },
        {
          "id": 215202,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pioglitazone </span></span></span></p>"
        },
        {
          "id": 215203,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Tesamorelin </span></span></span></p>"
        },
        {
          "id": 215204,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Which of the following is NOT used for the treatment of HIV-associated lipodystrophy?</span></span></span></p>",
      "unique_key": "Q4406246",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368747,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Metreleptin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin is a recombinant human leptin analog used to treat generalized lipodystrophy, not specifically HIV-associated lipodystrophy (HALS). HALS is a distinct form of lipodystrophy characterized by fat redistribution, often involving loss of subcutaneous fat in the face, limbs, and buttocks, and accumulation of visceral fat in the abdomen.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Metformin:</span></strong><span style=\"font-size:12.0pt\"> Can reduce abdominal fat in HALS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Pioglitazone:</span></strong><span style=\"font-size:12.0pt\"> Can be used to treat lipoatrophy and hepatic steatosis in HALS.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Tesamorelin:</span></strong><span style=\"font-size:12.0pt\"> A growth hormone-releasing hormone analog that helps reduce excess abdominal fat in HALS (but IGF-1 should be monitored). </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Metreleptin is used to treat generalized lipodystrophy and is not specifically used for HIV-associated lipodystrophy.</span></span></span></p>",
      "correct_choice_id": 215204,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19911,
      "choices": [
        {
          "id": 79605,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin </span></span></span></p>"
        },
        {
          "id": 79606,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Propranolol </span></span></span></p>"
        },
        {
          "id": 79607,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Spironolactone</span></span></span></p>"
        },
        {
          "id": 79608,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Enalapril</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 34-year-old man presents with resistant hypertension and a serum potassium level of 2.9 mEq/L, with normal creatinine. Which of the antihypertensives need not be stopped prior to the test you are about to perform to screen for the disease?</span></span></p>",
      "unique_key": "Q5095351",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368754,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Prazosin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The patient&#39;s presentation (resistant hypertension and hypokalemia) suggests possible primary aldosteronism. The most common test to screen for primary aldosteronism is the plasma aldosterone-to-renin ratio (ARR).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin (&alpha; -1 blocker):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Does not significantly interfere with the renin-angiotensin-aldosterone system (RAAS) and can be continued.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Propranolol (beta-blocker):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can lower plasma renin activity (PRA), potentially masking primary aldosteronism (false positive test). It should be stopped 2 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Spironolactone (mineralocorticoid receptor antagonist):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Directly affects aldosterone levels (false positive test). and should be stopped 4 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Enalapril (ACE inhibitor):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Can increase plasma renin activity, potentially leading to a false-negative result. It should be stopped 2 weeks before the test.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/14/screenshot-2024-08-14-165846.png\" style=\"height:275px; width:1000px\" /></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></u></strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: </span></u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prazosin (an &alpha;-1 blocker) does not significantly affect the renin-angiotensin-aldosterone system (RAAS) and can be continued during testing for primary aldosteronism. Other medications like beta-blockers, mineralocorticoid receptor antagonists, and ACE inhibitors should be stopped prior to testing.</span></span></span></p>",
      "correct_choice_id": 79605,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54024,
      "choices": [
        {
          "id": 215565,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1,25 (OH)2 D [calcitriol] levels are often normal.</span></span></span></p>"
        },
        {
          "id": 215566,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Expansion of the proliferating zone is seen in rickets. </span></span></span></p>"
        },
        {
          "id": 215567,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Looser&#39;s zones seen in osteomalacia occur near large arteries. </span></span></span></p>"
        },
        {
          "id": 215568,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Proximal myopathy can occur.</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient presents with fatigue and bone pain. Laboratory findings reveal low serum calcium, elevated parathyroid hormone (PTH), and low 25-hydroxyvitamin D [calcidiol] levels. Which of the following statements regarding this patient&#39;s condition is incorrect?</span></span></p>",
      "unique_key": "Q5310963",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368742,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Expansion of the proliferating zone is seen in rickets.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Three layers of chondrocytes are present in the normal growth plate: the reserve zone, the proliferating zone, and the hypertrophic zone. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rickets is characterized by impaired apoptosis and expansion of the hypertrophic chondrocyte layer (leading to expansion of the growth plate). Hence, chondrocytes cannot be replaced by osteoblasts, it leads to defective bone mineralization. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 1,25 (OH)2 D (calcitriol) levels are often normal:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;In severe vitamin D deficiency,&nbsp;there is a compensatory increase in PTH,&nbsp;which stimulates 1&alpha;-hydroxylase activity and can maintain normal calcitriol levels despite the deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Looser&#39;s zones seen in osteomalacia occur near large arteries:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;These radiolucent lines,&nbsp;also known as pseudofractures,&nbsp;are characteristic of osteomalacia and are often found adjacent to large arteries. These are often long, but only a few mm wide and common in scapula, pelvis and femoral neck. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Proximal myopathy can occur:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&nbsp;Muscle weakness,&nbsp;particularly in the proximal muscles,&nbsp;is a common symptom of severe vitamin D deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Summary: Vitamin D deficiency &ndash;</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Poor sunlight exposure, poor intake/malabsorption, increased demand (barbiturates, phenytoin, rifampin, nephrotic syndrome), impaired activation (liver or kidney disease, hypoparathyroidism, FGF23 excess) or resistance (VDR mutations).</span></span></span>\r\n\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Genetic causes: VDDR type I (1&alpha;-hydroxylase mutations, can be responsive to calcitriol) &amp; VDDR type 2 (VDR mutations, has alopecia and resistant to calcitriol).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Clinical Manifestations:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> &darr; S.Ca, &uarr; PTH (leading to &darr;PO4 and &uarr;ALP), proximal myopathy, and increased CV mortality.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Rickets in children before epiphyseal fusion.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Osteomalacia in adults. </span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Diagnosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Serum 25(OH)D level &ndash; best screening test.</span></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Vitamin D sufficiency is defined as &gt;50 nmol/L (&gt;20 ng/mL).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">&lt;37 nmol/L (&lt;15 ng/mL) &ndash; can lead to &uarr; PTH &amp; &uarr; ALP.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment:</span></strong></span></span>\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">RDA: 600 IU/d (1-70 years) and 800 IU/d (&gt;70 years). But up to 40000 IU/d is safe !</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Severe deficiency: Repletion (50000 IU/week for 3-12 weeks) followed by maintenance therapy (800 IU/d).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If 1&alpha;-hydroxylation is defective, use metabolites not requiring activation (calcitriol, doxercalciferol, alfacalcidol).</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Monitor treatment with serum and urinary calcium measurements. Target 24-h urinary Ca = 100&ndash;250 mg/d (&gt; 250mg/d should lead to reduction in dosage).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Expansion of the proliferating zone is not seen in rickets; it is the hypertrophic zone that is expanded.</span></span></span></p>",
      "correct_choice_id": 215566,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53975,
      "choices": [
        {
          "id": 215369,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iv, B-iii, C-ii, D-i</span></span></span></p>"
        },
        {
          "id": 215370,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iv, B-iii, C-i,D-ii</span></span></span></p>"
        },
        {
          "id": 215371,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iii, B-iv, C-i,D-ii</span></span></span></p>"
        },
        {
          "id": 215372,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">A-iii, B-iv, C-ii,D-i</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following:</span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/17/whatsapp-image-2024-08-17-at-121458-pm.jpeg\" style=\"height:246px; width:700px\" /></p>",
      "unique_key": "Q1554300",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368773,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. A) A-iv, B-iii, C-ii, D-i</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">If there is no residual thyroid function, the daily replacement dose of LT4 is usually 1.6 &mu;g/kg body weight (typically 100&ndash;150 &mu;g/d)</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Adult patients under 60 years old without evidence of heart disease may be started on 50&ndash;100 &mu;g of LT4 daily.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">For adults with indications to treat in a subclinical hypothyroidism treatment is administered by starting with a low dose of LT4 (25&ndash;50 &mu;g/d).</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">In the elderly, especially patients with known coronary artery disease, the starting dose of LT4 is 12.5&ndash;25 &mu;g/d. </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Standard Adult: 50-100 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Post thyroidectomy: 100-150 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Coronary Artery Disease: 12.5-25 &micro;g/day</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Subclinical Hypothyroidism: 25-50 &micro;g/day</span></span></span></li>\r\n</ul>",
      "correct_choice_id": 215369,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53977,
      "choices": [
        {
          "id": 215377,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Propranolol</span></span></span></p>"
        },
        {
          "id": 215378,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\">Propylthiouracil (PTU)</span></span></span></p>"
        },
        {
          "id": 215379,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Radioactive iodine (RAI)</span></span></span></p>"
        },
        {
          "id": 215380,
          "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydrocortisone</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 35-year-old woman with a history of Graves&#39; disease presents to the emergency department with fever, tachycardia, agitation, and vomiting. She recently underwent a dental procedure. Which of the following is the most appropriate initial treatment for her suspected condition?</span></span></span></p>",
      "unique_key": "Q2171098",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368775,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Propylthiouracil (PTU)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s presentation is consistent with thyrotoxic crisis (thyroid storm), a life-threatening complication of hyperthyroidism. PTU is the initial drug of choice due to its rapid onset of action and its ability to inhibit peripheral conversion of T4 to T3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Mortality of thyroid storm is 30% even with therapy. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. Propranolol (A): </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Can be used for cardio-protection but not immediately required.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Radioactive iodine (C)</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Not suitable for acute management of thyrotoxic crisis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Hydrocortisone (D)</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">: Adjunctive therapy in thyroid storm, can be added later.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Propylthiouracil (PTU) is the most appropriate initial treatment for thyrotoxic crisis (thyroid storm) due to its rapid onset of action and ability to inhibit peripheral conversion of T4 to T3.</span></span></span></p>",
      "correct_choice_id": 215378,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53985,
      "choices": [
        {
          "id": 215409,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TPO and Tg antibodies in the mother can cause fetal hypothyroidism.</span></span></span></p>"
        },
        {
          "id": 215410,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High Iodine intake increases the risk.</span></span></span></p>"
        },
        {
          "id": 215411,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells.</span></span></span></p>"
        },
        {
          "id": 215412,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Alcohol intake is protective.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding Hashimoto&rsquo;s thyroiditis? </span></span></p>",
      "unique_key": "Q5938502",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368780,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. A) TPO and Tg antibodies in the mother can cause fetal hypothyroidism.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Transplacental passage of Tg or TPO antibodies has no effect on the fetal thyroid (but transplacental passage of TSH-R blocking antibodies may induce transient neonatal hypothyroidism). </span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Genetic associations: HLA-DR3/DR4/DR5 &amp; CTLA-4 (weak). Down&rsquo;s and Turner&rsquo;s syndrome patients are at increased risk as well. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B. High Iodine intake increases the risk: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A high iodine or low selenium intake and decreased exposure to microorganisms in childhood increases risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Thyroid destruction is primarily mediated by the CD8+ cytotoxic T cells: </span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">True. Pathogenic effect of antibodies is restricted to a secondary role in amplifying an ongoing autoimmune response.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Alcohol intake is protective:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Smoking cessation transiently increases incidence, whereas alcohol intake seems protective. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Transplacental passage of Tg or TPO antibodies has no effect on the fetal thyroid, whereas TSH-R blocking antibodies may induce transient neonatal hypothyroidism.</span></span></span></p>",
      "correct_choice_id": 215409,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53994,
      "choices": [
        {
          "id": 215445,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">S. Tg is a sensitive marker post-surgery.</span></span></span></p>"
        },
        {
          "id": 215446,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Universal Target TSH post-surgery is 0.5-2 mIU/L. </span></span></span></p>"
        },
        {
          "id": 215447,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Patient should follow low Iodine diet for 1-2 weeks prior to <sup>I131 </sup>therapy.</span></span></span></p>"
        },
        {
          "id": 215448,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">TSH &gt; 25 is required at the time of I<sup>131</sup> therapy.</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is false regarding thyroid cancer treatment after thyroidectomy? </span></span></p>",
      "unique_key": "Q7345433",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368787,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Universal Target TSH post-surgery is 0.5-2 mIU/L.</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Target TSH post-surgery is based on the risk of recurrence. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Low risk of recurrence: 0.5&ndash;2.0 mIU/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Intermediate risk of recurrence: 0.1&ndash;0.5 mIU/L</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">High risk of recurrence &amp; metastatic disease: &lt;0.1 mIU/L </span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> Low-iodine diet for 1&ndash;2 weeks before treatment and serum TSH must be &gt;25 mIU/L at the time of therapy (usually achieved by thyroid hormone withdrawal or by rTSH injections). RAIA is not useful if tumour size &lt; 2cm or 2-4 cm + low risk. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. S. Tg is a sensitive marker post-surgery:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is true. Serum thyroglobulin (Tg) is a useful tumor marker for monitoring patients with papillary and follicular thyroid cancers after thyroidectomy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Patient should follow low Iodine diet for 1-2 weeks prior to I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is also true. A low iodine diet is recommended before radioactive iodine (RAI) therapy to enhance the uptake of iodine by any remaining thyroid tissue or cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. TSH &gt; 25 is required at the time of I131 therapy:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is generally true for patients with high-risk thyroid cancer. A higher TSH level helps stimulate the uptake of RAI by thyroid cancer cells.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The target TSH level post-surgery for thyroid cancer patients is based on the risk of recurrence, not universally 0.5-2 mIU/L. It ranges from 0.5-2.0 mIU/L for low risk, 0.1-0.5 mIU/L for intermediate risk, to &lt;0.1 mIU/L for high risk or metastatic disease.</span></span></span></p>",
      "correct_choice_id": 215446,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 19949,
      "choices": [
        {
          "id": 79757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV Aspart </span></span></span></p>"
        },
        {
          "id": 79758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV KCl </span></span></span></p>"
        },
        {
          "id": 79759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">IV NaHCO3 </span></span></span></p>"
        },
        {
          "id": 79760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">CT head</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 17-year-old boy with type 1 diabetes presents with vomiting, abdominal pain, lethargy, and drowsiness. His blood glucose is 350 mg/dL, and ABG shows the following &ndash; pH 7.24, S. Na 130 mEq/L, S. K 3.0 mEq/L, S. HCO3- 14 mEq/L, and S. Cl 88 mEq/L. His BP is 90/60 mm Hg, and IV fluids were rushed. Which of the following is the most appropriate next step in management?</span></span></p>",
      "unique_key": "Q6280882",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368788,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. B) IV KCl</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The patient is presenting with diabetic ketoacidosis (DKA) based on the clinical presentation (vomiting, abdominal pain, lethargy, drowsiness), elevated blood glucose (350 mg/dL), and metabolic acidosis on ABG (pH 7.24, bicarbonate 14 mEq/L). The patient also has significant hypokalemia (K+ 3.0 mEq/L) which is a common electrolyte disturbance in DKA due to increased urinary potassium loss.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Hypokalemia and Insulin:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin administration can further exacerbate hypokalemia by shifting potassium from the extracellular to the intracellular space.&nbsp;Therefore,&nbsp;potassium replacement should be initiated before starting insulin therapy in DKA.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Explanation</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. IV Aspart:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Insulin therapy is essential in DKA but should be started after correcting hypokalemia. Regular insulin is preferred for IV use in view of lesser cost but rapid acting analogs can also be used for IV use and are not contraindicated. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. IV NaHCO3:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Sodium bicarbonate is generally not recommended in DKA unless the pH is less than 6.9 or there are significant cardiac complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option D. CT head:</span></strong><span style=\"font-size:12.0pt\">&nbsp;Cerebral edema is a rare complication of DKA and usually occurs in children during treatment. It is not the immediate priority in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span style=\"font-size:12.0pt\">Educational Objective</span></u></strong><strong><span style=\"font-size:12.0pt\">:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Administer IV potassium chloride to correct hypokalemia before initiating insulin therapy in DKA to prevent severe hypokalemia.</span></span></span></p>",
      "correct_choice_id": 79758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53988,
      "choices": [
        {
          "id": 215421,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">De Quervain&#39;s thyroiditis </span></span></span></p>"
        },
        {
          "id": 215422,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Subacute lymphocytic thyroiditis</span></span></span></p>"
        },
        {
          "id": 215423,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Riedel&#39;s thyroiditis</span></span></span></p>"
        },
        {
          "id": 215424,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Hashimoto&#39;s thyroiditis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">A 30-year-old woman presents to her primary care physician 6 months after delivery with complaints of fatigue, cold intolerance, and weight gain for the last 3 weeks. She also reports feeling depressed and having difficulty concentrating. Her thyroid function tests reveal elevated TSH and low free T4 levels and positive anti-TPO antibodies. Which of the following is the most likely diagnosis?</span></span></span></p>",
      "unique_key": "Q8548669",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368782,
      "difficulty_level": "beginner",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Ans. B) Subacute lymphocytic thyroiditis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">The patient&#39;s postpartum presentation with a hypothyroid phase (fatigue, cold intolerance, weight gain, depression, elevated TSH, and low free T4) is characteristic of subacute lymphocytic thyroiditis, also known as painless thyroiditis. The presence of anti-TPO antibodies further supports this diagnosis, as it is an autoimmune condition. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Explanation:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option A. De Quervain&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a painful form of thyroiditis and they have an elevated ESR. Anti TPO antibodies are rarely positive in De Quervain&rsquo;s. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option C. Riedel&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> This is a rare fibrotic thyroiditis with a hard, fixed goiter.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Option D. Hashimoto&#39;s thyroiditis:</span></strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"> While also autoimmune, Hashimoto&#39;s typically presents with a gradual (chronic) onset of hypothyroidism and is less likely to occur postpartum.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Summary of post-partum thyroiditis:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Similar to De Quervain&rsquo;s thyroiditis, but painless and have normal ESR. </span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Occurs in 5% of women 3-6 months postpartum, termed postpartum thyroiditis.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Associated with TPO antibodies antepartum, 3x more common in type 1 diabetes.</span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Recovery is the rule. Annual follow-up recommended as some develop permanent hypothyroidism. May recur in subsequent pregnancies.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><u><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\">Educational Objective:</span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span dir=\"ltr\" lang=\"EN-IN\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Subacute lymphocytic thyroiditis, also known as painless thyroiditis, often presents postpartum with a hypothyroid phase and positive anti-TPO antibodies.</span></span></p>",
      "correct_choice_id": 215422,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 53954,
      "choices": [
        {
          "id": 215285,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Type 1 DM </span></span></span></p>"
        },
        {
          "id": 215286,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucocutaneous candidiasis </span></span></span></p>"
        },
        {
          "id": 215287,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hypoparathyroidism </span></span></span></p>"
        },
        {
          "id": 215288,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Adrenal insufficiency</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the first manifestation of APS 1?</span></span></span></p>",
      "unique_key": "Q9460332",
      "question_audio": null,
      "question_video": null,
      "map_id": 33368753,
      "difficulty_level": "intermediate",
      "subjects_id": [
        11
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Mucocutaneous candidiasis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chronic mucocutaneous candidiasis is the most common and often the first manifestation of autoimmune polyendocrine syndrome type 1 (APS-1). It usually appears in infancy or early childhood, often preceding the development of other components of the syndrome by years or even decades. It affects the mouth and nails more frequently than the skin and esophagus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation: </span></u></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Type 1 DM:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> It is uncommon in APS-1 but a common feature of APS-2. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypoparathyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Hypoparathyroidism typically develops after mucocutaneous candidiasis in APS-1.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Adrenal insufficiency:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Adrenal insufficiency is usually the last component of the classic triad to appear.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><u><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></u></strong><u> </u></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The first manifestation of APS-1 is typically mucocutaneous candidiasis, appearing in infancy or early childhood.</span></span></span></p>",
      "correct_choice_id": 215286,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}